>
Ivonescimab is a Summit Therapeutics Inc. program. Its PDUFA date is Nov 14, 2026, the FDA's goal date to complete review of the application. Every date links its source.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Sponsor: Summit Therapeutics Inc. (SMMT). Market-cap tier at the time we tracked it: Large. We track 8 catalyst events for this program: 7 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
Ivonescimab's PDUFA date is Nov 14, 2026. That is the FDA's goal date to complete review of the application; the agency can act earlier or extend it.
No FDA decision for Ivonescimab is in our archive yet.
Summit Therapeutics Inc. (SMMT).
FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.